Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.

Oncology nursing forum

Volumn 24, Issue 1, 1997, Pages 83-88

  Morrison, G B ^a   Bastian, A ^a   Dela Rosa, T ^a   Diasio, R B ^a   Takimoto, C H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; OXIDOREDUCTASE;

ADULT; CASE REPORT; FEMALE; HOSPITALIZATION; HUMAN; INBORN ERROR OF METABOLISM; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; METASTASIS; MIDDLE AGED; NEOPLASM; PATHOLOGY; PLEURA TUMOR; REVIEW;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; METABOLISM, INBORN ERRORS; MIDDLE AGED; NEOPLASMS; OXIDOREDUCTASES; PLEURAL NEOPLASMS; SEVERITY OF ILLNESS INDEX;

EID: 0030637112     PISSN: 0190535X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)